John Cox
Vorstandsvorsitzender bei DYNE THERAPEUTICS, INC.
Vermögen: 147 094 $ am 31.07.2023
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jason Rhodes | M | 54 | 7 Jahre | |
| Douglas Cole | M | 63 |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 9 Jahre |
| Josias Fantato De Pontes | M | 58 | 5 Jahre | |
| Tony Hunt | M | 60 | 10 Jahre | |
| Bart Henderson | M | 65 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | - |
| Nicolas Barthelemy | M | 58 | 19 Jahre | |
| Caroline Dorsa | F | 64 | 14 Jahre | |
| Nicole Murphy | F | - | 9 Jahre | |
| Rick Scalzo | M | 38 | 5 Jahre | |
| Natalie Yivgi-Ohana | M | - |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 Jahre |
| Stephen Sherwin | M | 75 | 14 Jahre | |
| Rohin Mhatre | M | 59 | 4 Jahre | |
| Mahalakshmi Radhakrishnan | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 5 Jahre |
| James Bylund | M | 61 | 4 Jahre | |
| John Najim | M | 48 | 5 Jahre | |
| Molly White | F | 64 | 4 Jahre | |
| Michael Hencke | M | - | 12 Jahre | |
| Ephraim Aharonson | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 Jahre |
| Qing Sarah Yuan | M | 53 | 5 Jahre | |
| Michael Thompson | M | - | 1 Jahre | |
| Steve Curran | M | - | 9 Jahre | |
| Catherine Stehman-Breen | M | 61 | 5 Jahre | |
| Uriel Halavee | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 Jahre |
| David Lubner | M | 60 | 4 Jahre | |
| Amy Reilly | F | 51 | 4 Jahre | |
| Dirk Kersten | M | 49 | 6 Jahre | |
| Timothy Harris | M | 74 | 9 Jahre | |
| Glenn Muir | M | 65 | 9 Jahre | |
| Carlo Incerti | M | 65 | 2 Jahre | |
| Edward Hurwitz | M | 60 | 6 Jahre | |
| Philip Johnson | M | 59 | 1 Jahre | |
| Eric Rowinsky | M | 67 | 14 Jahre | |
| Lisa Butterfield | F | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | - |
| Robert Windsor | M | - | 3 Jahre | |
| Torben Nissen | M | 53 |
Repertoire Immune Medicines, Inc.
 Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 2 Jahre |
| Steven Harr | M | 53 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 4 Jahre |
| Susan Hockfield | M | 73 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 Jahre |
| B. Parshall | F | 70 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 Jahre |
| Douglas A. Lauffenburger | M | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 8 Jahre |
| Daniel Wilson | M | 53 | 4 Jahre | |
| Anne Walker | F | 49 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 Jahre |
| Thomas-Christian Mix | M | 57 | 4 Jahre | |
| Debra Feldman | F | 54 | 4 Jahre | |
| John Davis | M | 56 | 4 Jahre | |
| Jonathan McNeill | M | 39 | 5 Jahre | |
| Philip Ashton-Rickardt | M | 60 | 3 Jahre | |
| Gordon Brooks | M | - | 1 Jahre | |
| Christine Gebski | F | 56 | 9 Jahre | |
| Vikas Gupta | M | - | 8 Jahre | |
| Shmuel Cabilly | M | 74 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | - |
| Stephen Berenson | M | 63 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 Jahre |
| Zeev Milbauer | M | 69 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 Jahre |
| Michael Dambach | M | 57 | 17 Jahre | |
| Ralf Kuriyel | M | 66 | 8 Jahre | |
| Wildon Farwell | M | 49 | 3 Jahre | |
| Chris Anderson | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Walter C. Herlihy | M | 72 | 19 Jahre | |
| Robert Essner | M | 76 |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | 11 Jahre |
| Andrea DiFabio | F | 55 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 14 Jahre |
| V. Lawlis | M | 72 |
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | 5 Jahre |
| William Kelly | M | 53 | 6 Jahre | |
| James Mullen | M | 65 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 23 Jahre |
| Joshua Brumm | M | 46 | 5 Jahre | |
| Daniel Anderson | M | - | 6 Jahre | |
| Jose-Carlos Gutiérrez-Ramos | M | 61 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 2 Jahre |
| Michel Vounatsos | M | 62 | 6 Jahre | |
| Glenn M. Reicin | M | 59 | 2 Jahre | |
| Alexander Denner | M | 54 | 14 Jahre | |
| Brian Posner | M | 62 | 14 Jahre | |
| Stelios Papadopoulos | M | 75 | 15 Jahre | |
| William Young | M | 79 | 11 Jahre | |
| William Rastetter | M | 75 | 19 Jahre | |
| Jon Snodgres | M | 58 | 9 Jahre | |
| Diantha Duvall | F | 52 | 4 Jahre | |
| Lynne Sullivan | F | 58 | 10 Jahre | |
| Martha Rook | F | 53 | 4 Jahre | |
| Carlos Costa | M | 51 | 7 Jahre | |
| Vanya Sagar | F | 49 | 6 Jahre | |
| Trevor Anthony Mill | M | 53 | 9 Jahre | |
| Brooke Story | F | 52 | 1 Jahre | |
| Kavita Patel | M | 50 | 3 Jahre | |
| Samantha Truex | F | - | 8 Jahre | |
| John Greene | M | 58 | 2 Jahre | |
| Glenn L. Cooper | M | 71 | 11 Jahre | |
| Jonathan Lieber | M | 54 | 2 Jahre | |
| Eric Shaff | M | 48 | 6 Jahre | |
| Geno Germano | M | 63 | - | |
| Richard Mulligan | M | 69 | 14 Jahre | |
| Eric S. Hoffman | M | 54 | 5 Jahre | |
| Robert A. Hamm | M | 72 | 7 Jahre | |
| Stephen Oesterle | M | 73 | 7 Jahre | |
| John Scarlett | M | 73 |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | 5 Jahre |
| Phillip Sharp | M | 79 | 31 Jahre | |
| Fred Hassan | M | 78 |
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | 4 Jahre |
| Gina Consylman | F | 52 | 3 Jahre | |
| Michael Gilman | M | 69 | 8 Jahre | |
| Robert Ruffolo | M | 74 | 7 Jahre | |
| Craig Eric Schneier | M | 76 | 8 Jahre | |
| Bethany Sensenig | F | 48 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 16 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 94 | 94,95% |
| Israel | 7 | 7,07% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
